{
    "clinical_study": {
        "@rank": "58698", 
        "arm_group": {
            "arm_group_label": "All participants"
        }, 
        "biospec_descr": {
            "textblock": "Monthly venous blood samples within the first half year and thereafter bi-monthly the rest\n      of the year. A subgroup of the subjects will also be invited for a visit within a week after\n      the former visit to assess the variation of the biomarkers within a week. The blood samples\n      will be assayed for peripheral blood mononuclear cells (PBMC) specificity, phenotype and\n      function as well as for islet autoantibodies (presence and precise titers), for autoantibody\n      isotypes and diabetes risk parameters. Finally C-peptide levels and residual beta cell\n      function will be measured three times during the study after a mix meal tolerance test\n      (MMTT) in subjects with T1D."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study is conducted in the United States of America (USA). The aim of this study is to\n      assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D),\n      type 2 diabetes (T2D) and healthy, non-diabetic subjects over a one year period."
        }, 
        "brief_title": "Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1", 
            "Diabetes Mellitus, Type 2", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  T1D\n\n          -  Male or female subjects diagnosed within the last 3 years and with good general\n             health based on medical history\n\n          -  Age above or equal to 14 years and below or equal to 40 years\n\n          -  Body weight above 45 kg\n\n          -  T2D\n\n          -  Male or female subjects diagnosed within the last 15 years with good general health\n             based on medical history\n\n          -  HbA1c between 6.5% and 10%\n\n          -  Body mass index (BMI) below 45 kg/m^2\n\n          -  Age above or equal to 18 and below 65 years\n\n          -  On insulin treatment\n\n          -  HS\n\n          -  Male or female subjects with good general heath based on medical history\n\n          -  Age above or equal to 18 years and below or equal to 40 years\n\n        Exclusion Criteria:\n\n          -  Any chronic disorder (besides T1D or T2D) or severe disease which, in the opinion of\n             the investigator, might jeopardize subject's safety or compliance with the protocol\n\n          -  Female of child-bearing potential who is pregnant, breast-feeding, or intends to\n             become pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "14 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Subjects with T1D, T2D and healthy subjects (HS) without personal or first degree family\n        history of autoimmunity of diabetes. The HS will be mean age-matched with the T1D\n        subjects."
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01900834", 
            "org_study_id": "INS-4099", 
            "secondary_id": "U1111-1140-1650"
        }, 
        "intervention": {
            "arm_group_label": "All participants", 
            "description": "The participants will not receive any treatment", 
            "intervention_name": "No treatment given", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 10, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08540"
                }, 
                "name": "Novo Nordisk Clinical Trial Call Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational Study Evaluating Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR,1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Variation in CD8 (cluster of differentiation) +T-cell specificity profiling", 
            "safety_issue": "No", 
            "time_frame": "Over a one year period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01900834"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Variation in CD4 +T-cell specificity profiling", 
                "safety_issue": "No", 
                "time_frame": "Over a one year period"
            }, 
            {
                "measure": "Change in stimulated C-peptide", 
                "safety_issue": "No", 
                "time_frame": "Baseline, one year"
            }, 
            {
                "measure": "Fluctuation in islet autoantibodies titers", 
                "safety_issue": "No", 
                "time_frame": "Over a one year period"
            }, 
            {
                "measure": "Variation in HbA1c (glycosylated haemoglobin)", 
                "safety_issue": "No", 
                "time_frame": "Over a one year period"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}